These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 21155690

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Targeting glucokinase activation for the treatment of type 2 diabetes--a status review.
    Sarabu R, Grimsby J.
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):631-7. PubMed ID: 16159025
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
    Xu J, Lin S, Myers RW, Addona G, Berger JP, Campbell B, Chen HS, Chen Z, Eiermann GJ, Elowe NH, Farrer BT, Feng W, Fu Q, Kats-Kagan R, Kavana M, Malkani S, McMasters DR, Mitra K, Pachanski MJ, Tong X, Trujillo ME, Xu L, Zhang B, Zhang F, Zhang R, Parmee ER.
    Bioorg Med Chem Lett; 2017 May 01; 27(9):2069-2073. PubMed ID: 28284804
    [Abstract] [Full Text] [Related]

  • 9. Glucokinase activators: Novo Nordisk's WO2008084044 and Array Biopharma's WO2008091770.
    Tilley JW.
    Expert Opin Ther Pat; 2009 Apr 01; 19(4):549-53. PubMed ID: 19441933
    [Abstract] [Full Text] [Related]

  • 10. Glucokinase activators in diabetes management.
    Coghlan M, Leighton B.
    Expert Opin Investig Drugs; 2008 Feb 01; 17(2):145-67. PubMed ID: 18230050
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
    Haynes NE, Corbett WL, Bizzarro FT, Guertin KR, Hilliard DW, Holland GW, Kester RF, Mahaney PE, Qi L, Spence CL, Tengi J, Dvorozniak MT, Railkar A, Matschinsky FM, Grippo JF, Grimsby J, Sarabu R.
    J Med Chem; 2010 May 13; 53(9):3618-25. PubMed ID: 20405948
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Advances in the study of glucokinase and small molecule glucokinase activators].
    Li YQ, Feng ZQ, Song HR, Guo YS, Guo ZR.
    Yao Xue Xue Bao; 2006 May 13; 41(5):390-4. PubMed ID: 16848312
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
    Xu J, Lin S, Myers RW, Trujillo ME, Pachanski MJ, Malkani S, Chen HS, Chen Z, Campbell B, Eiermann GJ, Elowe N, Farrer BT, Feng W, Fu Q, Kats-Kagan R, Kavana M, McMasters DR, Mitra K, Tong X, Xu L, Zhang F, Zhang R, Addona GH, Berger JP, Zhang B, Parmee ER.
    Bioorg Med Chem Lett; 2017 May 01; 27(9):2063-2068. PubMed ID: 28284809
    [Abstract] [Full Text] [Related]

  • 20. Allosteric activators of glucokinase: potential role in diabetes therapy.
    Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF.
    Science; 2003 Jul 18; 301(5631):370-3. PubMed ID: 12869762
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.